Operator: Good day, everyone and welcome to Pfizer's Third Quarter 2013 Earnings Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.
Charles E. Triano - IR: Thank you, operator. Good morning and thank you for joining us today to review Pfizer's third quarter 2013 performance. I'm joined today as usual by our Chairman and CEO, Ian Read; Frank D'Amelio, our CFO; Mikael Dolsten, President of Worldwide Research and Development, Geno Germano, President and General Manager of Specialty Care and Oncology; Amy Schulman, General Counsel, Business Unit Lead for our Consumer Business and John Young, President and General Manager of Primary Care.
The slides that will be presented on this call can be viewed on our home page pfizer.com, by clicking on the link for Pfizer Quarterly Corporate Performance Third Quarter 2013 located in the Investor Presentations section at the lower right hand corner of this page.
Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements and that actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer's 2012 Annual Report on Form 10-K, and in our reports on Forms 10-Q and 8-K.
The discussions during this call will include certain financial measures that were not prepared in accordance with Generally Accepted Accounting Principles. Reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in Pfizer's current report on Form 8-K dated today, October 29, 2013.
With that, I'll now turn the call over to Ian Read. Ian?
Ian Read - Chairman and CEO: Thank you, Chuck. I'll begin with some comments on the quarter. overall we delivered good operational performance, generated solid financial results and continued to see steady progress with many of our inline products and pipeline assets.
Operationally revenues for the oncology business grew 26% due to the continued strong performance of new products primarily Inlyta and Xalkori.
We also had another strong quarter operationally from Lyrica which grew 11% and from Celebrex which grew 13%.
Despite macroeconomic and other factors the emerging markets business grew 5%. operationally, primarily due to volume growth, the key products in the Primary Care area such as Lipitor, Norvasc, Lyrica and Celebrex especially in China. We still anticipate achieving mid-single-digit growth in emerging markets for the year.
Turning to an update on our recently launched and approved products and pipeline assets; earlier this month we received FDA approval of Duavee our novel combination therapy for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and the prevention of postmenopausal osteoporosis and we anticipate launching this product in the U.S. during the first quarter of next year.